Clarinase

Quick links to important sections

Clarinase

Method of action: Antitussive, Nasal Preparations

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clarinase

Quick Facts

Property Description
Active Ingredients Loratadine, Pseudoephedrine Sulfate
Form Extended-release Tablet (Modified-release)
Pharmacological Class Fixed-dose Antihistamine / Sympathomimetic Amine Decongestant
Common Use Relief of Allergic Rhinitis symptoms and Nasal Congestion
Origin Synthetic

What Type of Medicine is Clarinase? (Definition and Classification)

Clarinase is defined as a fixed-dose combination (FDC) preparation derived from synthetic compounds, engineered for oral administration and systemic absorption. Pharmacologically, it is classified as a combination of a second-generation antihistamine and a sympathomimetic amine decongestant. The product is primarily supplied as an extended-release tablet or modified-release tablet, a format intended to provide prolonged therapeutic effects. This specific dual-action profile is clinically recognized for managing combined allergy symptoms, distinguishing it from single-agent allergy treatments.

Composition: Loratadine and Pseudoephedrine Sulfate (Active Ingredients)

The preparation is composed of two primary active ingredients: Loratadine and Pseudoephedrine Sulfate. Loratadine acts as a peripheral H1-receptor antagonist, blocking the activity of histamine, the substance that triggers allergic symptoms. The Pseudoephedrine Sulfate component is an alpha-adrenergic agonist that specifically causes vasoconstriction—the narrowing of blood vessels—in the nasal passages. The fixed concentration of these compounds in the tablet ensures the simultaneous delivery of both antihistamine and decongestant effects.

General Purpose of the Dual-Action Preparation (Therapeutic Utility)

The general purpose of this dual-action preparation is the efficient, simultaneous relief of the diverse symptoms associated with allergic rhinitis and seasonal allergies. The Loratadine component addresses core allergic manifestations such as sneezing, itching, and itchy/watery eyes. Concurrently, the Pseudoephedrine component targets physical discomfort, specifically reducing the swelling of mucosal tissues to alleviate nasal congestion and sinus pressure. This synergistic effect is beneficial for improving patient comfort during periods of high allergen exposure.

Regulatory References

  1. FDA Drug Label: Loratadine/Pseudoephedrine
  2. NIH/PubMed Study on Loratadine/Pseudoephedrine

What side effects are possible with Clarinase?

The official safety profile for the Loratadine and Pseudoephedrine Sulfate combination is structured around adverse reactions categorized by their frequency and the physiological system affected, according to government regulatory documentation.

Adverse Reaction Classifications

Classification Examples of Documented Effects
Common Insomnia, Dry mouth, Headache, Somnolence (Drowsiness), Nervousness, Dizziness, Fatigue.
Uncommon Tachycardia (fast heart rate), Palpitations, Nausea, Hypertension (high blood pressure), Tremor.
Very Rare Anaphylaxis (severe allergic reaction), Hepatic dysfunction.

Adverse effects are documented across several System-Organ Classes, with the Nervous System and Cardiovascular System being the primary domains. Effects such as Insomnia and Nervousness are generally associated with the Pseudoephedrine component, which can also rarely lead to more serious Cardiovascular or Central Nervous System (CNS) events.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions officially noted include Hypersensitivity reactions (e.g., Anaphylaxis) and rare cases of Hepatic dysfunction. The safety profile also includes mandatory restrictions on use for individuals with specific pre-existing health conditions, as defined in the official labeling.

Safety-related restrictions include individuals with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, urinary retention, and those receiving Monoamine Oxidase Inhibitors (MAOIs), as these conditions increase the risk of adverse outcomes from the sympathomimetic component.

Population-Specific Safety Notes caution that older adults may exhibit increased sensitivity to the cardiovascular and CNS effects. The combination product is generally avoided in patients with severe hepatic impairment or severe renal impairment due to altered drug clearance, as explicitly stated in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose from the Loratadine and Pseudoephedrine Sulfate combination by focusing on documented physiological manifestations and mandated emergency actions. Taking more than directed is associated with an expected symptom profile involving both components.

Overdose manifestations documented in regulatory sources include central nervous system (CNS) effects such as drowsiness, somnolence, agitation, and headache. Cardiovascular signs, specifically tachycardia (rapid heart rate), are also listed as a manifestation of overdose. The elderly population may be at an increased risk of cardiotoxicity during an overdose.

Required Emergency Actions

In case of suspected overdose, regulatory guidance mandates that individuals get medical help or contact a Poison Control Center right away.

Immediate medical attention is required when severe clinical signs are present, including seizures, collapse, trouble breathing, or a sudden, severe headache. These severe manifestations may signal the risk of serious, documented outcomes such as cardiac arrhythmias or cerebrovascular events (e.g., PRES/RCVS).

Management is defined as symptomatic and supportive treatment. Specific procedures like the administration of activated charcoal and considerations for cardiac monitoring are regulatory-documented measures.

Therapeutic Uses of Clarinase

This combination preparation is commonly used to help address symptom clusters that may become intense or disruptive, supporting patients during episodes of heightened discomfort.

The therapeutic information for this medication shows it is applied in situations involving certain distressing symptoms associated with acute or disruptive episodes. The preparation is relevant in conditions characterized by periods of heightened symptoms, such as Seasonal Allergic Rhinitis (Hay Fever) and Perennial Allergic Rhinitis.

It is used for managing symptom clusters related to inflammatory or irritative states, including sneezing, runny nose, itchy eyes, and itching of the throat, as well as nasal congestion and sinus pressure. This offers symptomatic relief that may assist with maintaining functional stability during symptomatic periods. The combination is applied in scenarios where additional management of discomfort is required, helping manage symptoms related to both irritative states and noticeable physiological strain.


Quick Fact: Symptom Clusters Targeted

Symptom Domain Key Manifestations
Inflammatory/Irritative Symptoms Sneezing, runny nose, ocular and nasal itching
Symptoms related to physical discomfort Stuffy nose, nasal blockage, sinus pressure

Regulatory References

  1. NIH DailyMed service

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Clarinase

Clarinase (loratadine/pseudoephedrine) is officially documented for use in adults and adolescents 12 years of age and over who do not have specific exclusionary medical conditions. The official regulatory labeling defines strict populations for whom use is contraindicated and others for whom special caution is required.

Contraindicated Populations (Must Not Use):

Category Exclusionary Condition
Age Children under 12 years of age
Allergy Known hypersensitivity to the active ingredients (loratadine, pseudoephedrine), adrenergic agents, or any other component
Cardiovascular Severe hypertension (high blood pressure) or severe coronary artery disease
Ocular/Urogenital Narrow-angle glaucoma or urinary retention
Concomitant Drug Use Patients taking or who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days

Restricted or Cautionary Use:

Use of Clarinase requires caution or special consideration in patients with pre-existing conditions such as diabetes mellitus, hyperthyroidism, increased intraocular pressure, or prostatic hypertrophy. For those with severe renal insufficiency, a lower initial daily dose may be necessary. Use is generally avoided in patients with severe hepatic insufficiency because the fixed-dose combination cannot be adjusted for the individual components.

Pregnancy and Lactation Status:

Safe use during pregnancy and lactation (breastfeeding) has not been established. The product should be used only if the potential benefit justifies the potential risk, and a decision must be made to either discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific restrictions and requirements for co-administering this combination product (Loratadine and Pseudoephedrine Sulfate) with other substances.

Contraindicated Combinations and Restrictions

Classification Interacting Entity Constraint and Outcome
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Prohibited for co-administration or within 14 days of stopping MAOI therapy due to risk of severe hypertensive crisis.
Contraindicated Ergot Derivatives Prohibited due to enhancement of Pseudoephedrine’s vasoconstricting effect, leading to increased blood pressure.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with enzyme inhibitors like Ketoconazole, Erythromycin, or Cimetidine is documented to cause a pharmacokinetic interaction, resulting in increased plasma concentrations (exposure) of Loratadine.

Pharmacodynamic interactions arise when combining with other sympathomimetics (decongestants), which are advised against due to additive effects. Furthermore, Pseudoephedrine may reduce the antihypertensive effects of certain drugs, including Methyldopa. Concurrent use with Digitalis may increase the risk of ectopic pacemaker activity.

Food and Population-Specific Notes

A high-fat meal is documented to cause a drug-food interaction, significantly increasing the overall exposure (AUC) of Loratadine. For patients with severe hepatic insufficiency, use should be avoided due to the risk of accumulation, as noted in the regulatory profile.

Mechanism of Action

How Clarinase Works


Targeting Histamine and Inflammatory Signaling

The mechanism begins with loratadine, which acts on peripheral Histamine H1-receptors. Its action, characterized as inverse agonism, helps suppress the signaling pathway initiated by the chemical messenger histamine. This molecular event modifies the cascade by limiting the increase in capillary wall permeability and reducing subsequent mediator activity related to the targeted receptor systems.


Modulating Autonomic Vascular Tone

The second mechanism, driven by pseudoephedrine, engages the Sympathetic Nervous System by modulating the alpha1-adrenergic receptors on blood vessel walls. By promoting the release of norepinephrine and/or acting directly, this process causes the smooth muscles around the vessels in the respiratory lining to contract. This targets signaling patterns characteristic of autonomic control and modulates activity within the targeted pathways, leading to vasoconstriction, resulting in a reduction of tissue volume.


Complementary Dual-Pathway Modulation

The two distinct mechanisms operate in synergy, providing modulation across key mechanistic domains. This dual-pathway approach simultaneously addresses both the chemical mediator signaling (histamine) and the physiological vascular response (adrenergic activation). This modulates both peripheral (histamine) and autonomic (adrenergic) pathways.

Dosage and Administration Information

Clarinase (loratadine and pseudoephedrine sulfate) is an extended-release combination product used to relieve symptoms associated with allergic rhinitis and the common cold.

Administration and Dosage

The tablets should be swallowed whole with a glass of water. They must not be divided, crushed, broken, or chewed, as this would interfere with the extended-release mechanism of the medicine and may lead to serious side effects. The dose is typically taken with or without food, but should be administered at a fixed time to maintain symptom relief.

The recommended dosage depends on the specific product formulation (12-hour or 24-hour release):

Age Group Dosage (12-Hour Release) Max Dose (24 Hours)
Adults and Children 12 years One tablet every 12 hours 2 tablets
Age Group Dosage (24-Hour Release) Max Dose (24 Hours)
Adults and Children 12 years One tablet once daily 1 tablet

For children under 12 years of age, the use of this combination medicine is generally not recommended, and appropriate dosing should be determined by a healthcare provider.

Missed and Overdoses

If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose; in that case, skip the missed dose. Do not take two doses at once to compensate for a forgotten dose. If an overdose is suspected, seek immediate medical attention, even if no discomfort or signs of poisoning are present. Patients with kidney or liver disease should consult a doctor, as dose adjustments may be necessary due to altered drug clearance.

Recent Clinical Evidence

Clarinase: Recent Clinical Evidence

Clarinase is a combination medication containing loratadine (an antihistamine) and pseudoephedrine sulfate (a decongestant). Clinical evidence for this combination primarily focuses on its use in managing the symptoms of seasonal allergic rhinitis (SAR), particularly when nasal congestion is present.


Effectiveness in Allergic Rhinitis

Randomized controlled studies have evaluated the effectiveness of the loratadine-pseudoephedrine combination compared to placebo and to its individual components alone.

  • Symptom Relief: Research consistently shows that the combination is superior to placebo in reducing overall symptoms of SAR. Symptom scores, including those for sneezing, rhinorrhea (runny nose), itching, and nasal congestion, were often measured as primary outcomes in these trials.
  • Nasal Congestion: The addition of pseudoephedrine is integral to addressing nasal stuffiness. Studies have indicated that the combination is more effective at relieving nasal congestion compared to loratadine taken alone.
  • Comparative Analysis: When compared to its individual components, reductions in mean symptom scores were observed to be numerically greater in patients receiving the combination.

Safety and Tolerability

Clinical trials have examined the safety profile of the combination. The most frequently reported adverse effects included symptoms attributable to the pseudoephedrine component, which is a sympathomimetic amine.

Common Adverse Events Observed
Insomnia
Dry mouth
Nervousness
Headache
Somnolence (drowsiness)

In controlled clinical trials using the recommended dosage, the incidence of reported adverse events was often similar to those reported with placebo, with the notable exception of insomnia and dry mouth.

Frequently Asked Questions (FAQ)

Common questions about Clarinase (FAQ)


Q: What is the main difference between Clarinase and regular Claritin?

Clarinase is officially classified as a fixed-dose combination product because it contains two active ingredients: loratadine, which is the antihistamine found in regular Claritin, and pseudoephedrine sulfate, which is a decongestant. The addition of the decongestant component gives Clarinase a dual action not present in the single-ingredient formulation.


Q: What food or drinks should I avoid when taking Clarinase?

Official drug documents note that taking Clarinase with a high-fat meal may increase the amount of loratadine the body absorbs. Regulatory warnings mention that drinking alcohol may increase the likelihood of experiencing certain side effects associated with the medication.


Q: Can older adults use Clarinase, and are there special considerations?

Official safety documents mention that older adults may exhibit increased sensitivity to the effects of the medication on the central nervous system and the heart and circulatory system. Because of this potential for increased sensitivity, special consideration is necessary when the drug is used by this population.


Q: How long can a person continuously take Clarinase before needing a break?

Official product information for some formulations indicates that use is typically intended to be for a short duration, such as up to 3 months, unless the recommended duration is modified by a healthcare provider.


Q: Can Clarinase be taken with over-the-counter pain relievers like paracetamol?

The pseudoephedrine component is often included in other cold and flu products, sometimes combined with pain relievers. Regulatory cautions indicate the importance of checking the labels of all other medicines, including over-the-counter products, to avoid accidentally taking too much of a similar decongestant ingredient.


Q: Is Clarinase the same as Claritin-D?

Yes, regulatory drug classifications confirm that Clarinase and Claritin-D contain the same fixed-dose combination of active ingredients: loratadine (antihistamine) and pseudoephedrine sulfate (decongestant).


Q: Does taking Clarinase affect the results of allergy skin tests?

Official classification states that the loratadine component acts as an antihistamine, which works by blocking the effects of histamine. Due to this function, it is noted in medical guidance documents that antihistamines may interfere with the results of certain allergy skin tests.


Q: Does Clarinase cause drowsiness or make you sleepy?

Although the product is generally classified as non-drowsy, official safety documents list Somnolence (drowsiness) as a common adverse event. Warnings also note that taking more than the recommended amount may increase the chance of experiencing drowsiness.


Q: How quickly does Clarinase start to work after taking it?

Studies examining the loratadine component, which is immediately available in the tablet, have reported the onset of symptom relief in adults as quickly as 75 minutes after administration.


Q: Is there any risk of becoming dependent on Clarinase?

Dependency is not typically listed as a common adverse reaction in official safety documents for the prescribed use. However, the pseudoephedrine component is highly regulated in many regions due to its potential for misuse.


Q: Are there any known issues with taking Clarinase and blood thinners?

The decongestant component of Clarinase can affect blood pressure. Because of this, regulatory guidance indicates that products like this should be used with caution in individuals taking blood thinners (anticoagulants).


Q: Can Clarinase cause difficulty sleeping or insomnia?

Yes, the official safety profile for the product lists Insomnia (difficulty sleeping) as a common adverse event. This effect is generally associated with the stimulant properties of the pseudoephedrine component.


Q: Why do some people say Clarinase makes them feel jittery?

Official safety documents list Nervousness as a common side effect. This feeling is consistent with the drug’s mechanism of action, which includes the effects of pseudoephedrine, classified as a sympathomimetic amine.


Q: Can Clarinase be used for treating sinus pain and pressure?

Official indications for use include the temporary relief of symptoms associated with allergies, including nasal congestion and sinus pressure, due to the decongestant component.


Q: Are there different strengths of Clarinase available?

Official drug registers confirm the combination product is available in different strengths that correspond to the release duration. Examples include the 12-hour formulation and the higher-strength 24-hour formulation.


Q: Does Clarinase work for seasonal allergies or year-round allergies?

The product is primarily indicated for the relief of symptoms associated with Seasonal Allergic Rhinitis (SAR). However, research has also been conducted to examine its effectiveness in perennial allergic rhinitis (PAR), which are year-round allergies.


Q: Does the efficacy of Clarinase decrease over time (tolerance buildup)?

Clinical data related to the loratadine component has shown no evidence of tolerance developing to the antihistamine effect after 26 days of continuous dosing.


Q: Why is Clarinase sometimes used by people who travel on planes?

The decongestant ingredient, pseudoephedrine, works by narrowing blood vessels in the nasal passages. This action is sometimes described as being used to help relieve ear pain and blockage that can be caused by pressure changes during air travel.


Q: Does Clarinase contain gluten or lactose?

Official product labeling for some formulations lists inactive ingredients, including anhydrous lactose. Ingredients are not typically listed as containing gluten.


Q: Does Clarinase contain a steroid?

No. Official documents classify Clarinase as a combination of an Antihistamine and a Sympathomimetic Amine Decongestant. It does not belong to the pharmacological class of steroids.


Q: Is there research that compares the components of Clarinase to other dual-ingredient drugs?

Yes, clinical trials and published research have been conducted to evaluate the effectiveness and tolerability of the loratadine/pseudoephedrine combination when compared to other dual-ingredient allergy and congestion medications.


Q: Is Clarinase known to interact with herbal supplements?

Regulatory guidance indicates that there is generally not enough safety information available to determine the effect of combining this product with herbal remedies or supplements, and the product should be used with caution.

How should Clarinase be stored and disposed of?

Storage Requirements

Clarinase (Loratadine and Pseudoephedrine Sulfate) must be stored at a controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and must be protected from light and moisture. It is necessary to keep the medicine in a dry place and to keep from freezing.

To ensure product integrity, the tablets must remain in their original blister pack. The medicine should not be used if the packaging is torn, broken, or shows signs of tampering. It is a mandatory requirement to keep the tablets out of the reach of children.


Disposal Instructions

Official disposal guidance recommends utilizing drug take-back programs as the preferred method for discarding unused or expired Clarinase. If a take-back site is unavailable, the tablets should be mixed with an unappealing substance, placed into a sealed container, and then thrown in the household trash. The tablets must not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clarinase found in:

A-Z Index: